Table 1. Summary of included studies.
| Study/year | Patient Numbers | Method | TP | FP | FN | TN | SEN | SPE | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|---|
| Vilmann P et al. (18) | 28 | EUS-FNA+EBUS-TBNA | 28 | 0 | 0 | 28 | 1.00 | 1.00 | 1.00 | 1.00 |
| Wallace MB et al. (19) | 138 | EBUS-TBNA+EUS-FNA | 39 | 0 | 3 | 96 | 0.93 | 1.00 | 1.00 | 0.97 |
| Szlubowski A et al. (20) | 120 | EUS-FNA+EBUS-TBNA | 19 | 2 | 9 | 90 | 0.68 | 0.98 | 0.90 | 0.91 |
| Annema JT et al. (21) | 123 | EUS-FNA+EBUS-TBNA | 56 | 0 | 10 | 57 | 0.85 | 1.00 | 1.00 | 0.85 |
| Herth FJ et al. (28) | 139 | EBUS-TBNA+EUS-B-FNA | 72 | 0 | 3 | 57 | 0.96 | 1.00 | 1.00 | 0.95 |
| Hwangbo B et al. (29) | 143 | EBUS-TBNA+EUS-B-FNA | 41 | 0 | 4 | 98 | 0.91 | 1.00 | 1.00 | 0.96 |
| Ohnishi R et al. (22) | 110 | EBUS-TBNA+EUS-FNA | 28 | 0 | 11 | 71 | 0.72 | 1.00 | 1.00 | 0.87 |
| Szlubowski A et al. (23) | 110 | EUS-FNA+EBUS-TBNA | 55 | 1 | 5 | 49 | 0.92 | 0.98 | 0.98 | 0.91 |
| Kang HJ (group A) et al. (24) | 74 | EBUS-TBNA+EUS-FNA | 29 | 0 | 5 | 40 | 0.85 | 1.00 | 1.00 | 0.89 |
| Kang HJ (group B) et al. (24) | 74 | EUS-FNA+EBUS-TBNA | 23 | 0 | 2 | 49 | 0.92 | 1.00 | 1.00 | 0.96 |
| Liberman M et al. (25) | 166 | EBUS-TBNA+EUS-FNA | 41 | 0 | 5 | 120 | 0.89 | 1.00 | 1.00 | 0.96 |
| Lee KJ et al. (30) | 37 | EBUS-TBNA+EUS-B-FNA | 29 | 0 | 0 | 8 | 1.00 | 1.00 | 1.00 | 1.00 |
| Oki M et al. (31) | 146 | EBUS-TBNA+EUS-B-FNA | 24 | 0 | 9 | 113 | 0.73 | 1.00 | 1.00 | 0.93 |
| Szlubowski A et al. (32) | 106 | EBUS-TBNA+EUS-B-FNA | 38 | 2 | 18 | 48 | 0.68 | 0.96 | 0.95 | 0.73 |
| Crombag LMM et al. (33) | 244 | EBUS-TBNA+EUS-B-FNA | 84 | 19 | 19 | 122 | 0.82 | 0.87 | 0.82 | 0.87 |
| Tutar N et al. (26) | 20 | EBUS-TBNA+EUS-FNA | 10 | 0 | 1 | 9 | 0.91 | 1.00 | 1.00 | 0.90 |
FN, number of false negatives; FP, number of false positives; NPV, negative predictive value; PPV, positive predictive value; SEN, sensitivity; SPE, specificity; TN, number of true negatives; TP, number of true positives.